| Date |
Title |
Download |
| 31 Aug 2010 |
Annual Statutory Accounts 2010
The Company has released its 2010 Annual Report and the full report is available on its website. |
|
| 11 Sep 2008 |
Presentation of pre-clinical activity of CAVATAK in Human Brain Cancer :Coxsackievirus A21 Oncolytic Virotherapy as a Novel Treatment for Malignant Glioma
|
Acrobat
1272 Kb
|
| 11 Sep 2008 |
Immune response to an Oncolytic Human Picornavirus, Coxsackievirus A21 (CAVATAKTM) in Patients with Late Stage Melanoma
|
Acrobat
494 Kb
|
| 07 Feb 2008 |
Systemic targeting of metastatic human breast tumor xenografts by Coxsackievirus A21
|
Acrobat
31 Kb
|
| 01 Feb 2008 |
Oncolytic activity of human enteroviruses against human prostate cancer
|
Acrobat
46 Kb
|
| 01 Jan 2007 |
Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma
|
Acrobat
305 Kb
|
| 10 Jan 2005 |
Oncolysis of vascular malignant human melanoma tumors by Coxsackievirus A21
|
Acrobat
631 Kb
|
| 01 Jan 2005 |
Oncolysis of Human Ovarian Cancers by Echovirus Type 1
|
Acrobat
4064 Kb
|
| 01 Nov 2004 |
Enhanced Cellular Receptor Usage by a Bioselected Variant of Coxsackievirus A21
|
Acrobat
2104 Kb
|
| 01 Nov 2004 |
Novel Role for Decay-Accelerating Factor in Coxsackievirus A21-Mediated Cell Infectivity.
|
Acrobat
391 Kb
|
| 01 Feb 2004 |
Enterovirus Capsid Interactions with Decay-Accelerating Factor Mediate Lytic Cell Infection
|
Acrobat
209 Kb
|
| 01 Jan 2004 |
Systemic Therapy of Malignant Human Melanoma Tumors by a Common Cold-Producing Enterovirus, Coxsackievirus A21
|
Acrobat
616 Kb
|
| 18 Jul 2003 |
Cellular Receptor Interactions of C-Cluster human group A Coxsackieviruses
|
Acrobat
515 Kb
|
| 02 Dec 1999 |
Cytoplasmic interactions between decay-accelerating factor and intercellular adhesion molecule-1 are not required for coxsackievirus A21 cell infection
|
Acrobat
582 Kb
|
| 01 Sep 1999 |
Picornavirus Receptor Down-Regulation by Plasminogen Activator Inhibitor Type 2
|
Acrobat
1311 Kb
|
